RESEARCH TRIANGLE PARK, N.C., Jan. 30, 2013 /PRNewswire/ -- Marken today announced the expansion of its internal regulatory and technical expertise with the promotion of Dan Bell to Vice President. The announcement follows an industry-led panel discussion hosted by Marken in Farmingdale, New York on January 15th. The panel was convened to shed light on the growing complexity of clinical supply chain management. Industry experts shared a wide range of perspectives relating to clinical trials risk, cost, resources and security.
Rafik Bishara, Ph.D., current Chair of the Pharmaceutical Cold Chain Interest Group (PCCIG) within the Parenteral Drug Association (PDA), said: "There is a very clear shift in how we should view 'cold chain' logistics, especially with the growth of biologically derived drugs and vaccines. Supplier's Quality Systems will need to be expanded to include increased tracking for chain of custody assurance, more reliable data monitoring and compliance with changing customs requirements in developing countries. This shift will go far beyond our current understanding and application of Good Distribution Practices." The panel was moderated by Pfizer's Bruce Guenter, who said: "Our industry will certainly demand more reliable monitoring of data and will need to ensure compliance with the changing regulations. It is vital to our industry that we continue to coordinate collaborative exchanges like this to ensure that we are ready, prepared, and ahead of the curve."
Marken has long been known for its high quality, compliant and reliable service to the pharmaceutical industry. A new unit has been formed, expanding on Marken's already strong legacy of compliance, and has promoted Dan Bell to a newly created position of Vice President, Regulatory Compliance and Technical Affairs. Wes Wheeler, Marken's CEO, said: "Dan has been instrumental to Marken's growth and has developed strong relationships with some of the industry's most demanding clients. He is recognized in the industry as a frequent speaker on important issues in cold chain logistics and regulatory challenges. He is passionate about advancing new techniques, finding solutions and expanding the knowledge base in clinical logistics."
Mr. Bell is also a licensed customs broker and a certified customs specialist in the United States. He will join Marken's Executive Committee and work with Marken to set objectives for 2013 and beyond.
Marken is the leading global clinical supply chain solutions provider dedicated to the pharmaceutical and life sciences industries, supporting over 49,000 clinical investigators in more than 150 countries. Marken integrates Depot and Logistics services into solutions that extend the reach of clinical trials to even the most remote treatment naive geographies.